Daniel M. McCalley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daniel M. McCalley has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Claudia B. Padula
Sierra‐Pacific Mental Illness Research and Education Clinical Centers Veterans Affairs Palo Alto Healthcare System Palo Alto California USA
3 shared publications - Colleen A. Hanlon
Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, USA
3 shared publications - Brian Knutson
Department of Psychology, Stanford University
2 shared publications Claudia B. Padula
Veterans Affairs Palo Alto Healthcare System, Sierra Pacific Mental Illness Research Education and Clinical Center (MIRECC), Palo Alto, USA
2 shared publicationsColleen A. Hanlon
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina; Department of Neurosciences, Medical University of South Carolina, Charleston, South Carolina; Department of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, South Carolina; Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, South Carolina
2 shared publicationsEric P. Kraybill
Veterans Affairs Palo Alto Healthcare System, Sierra Pacific Mental Illness Research Education and Clinical Center (MIRECC), Palo Alto, CA, United States
2 shared publications
Latest Publications
- 16 December 2025
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 51 (4) , 722-731
Females have shorter scalp-to-cortex distances and receive stronger TMS electrical fields: Implications for clinical treatment
The strength of a given transcranial magnetic stimulation (TMS) pulse decays rapidly with distance. Male and female bone structure reliably differs by the shape of the frontal bone, mandible, and inion. Given the morphology of these structures constitutes much of the scalp-to-cortex distance (STCD), we hypothesized that females have shorter STCDs and thereby receive stronger TMS electrical field strengths, relative to males. Head models (n = 411; 197 female, 214 male) were constructed from MRIs of healthy participants (ages 18–90). STCD and peak electrical field strength were measured at 50 EEG 10–20 sites (SimNIBSv3.2). Linear models (bootstrapped and Benajamini-Hochberg multiple comparison-corrected) evaluated the influence of sex on STCD and electrical field strength. Females had significantly shorter STCDs at 27/50 sites and stronger TMS electrical fields at 18/50. When normalized by data collected at the motor cortex, females had significantly shorter STCD at 40/49 sites and stronger TMS electrical fields at 29/49 sites. The largest effect size differences were detected at the frontal, temporal, and occipital poles, and the cerebellum. Interestingly, STCD at the motor cortex was not different between sexes, suggesting the motor cortex-based dosing strategies produce unequal electrical fields between sexes. These data provide a mathematically grounded explanation for sex-differences in clinical outcome and may be relevant to other modalities that depend on electromagnetic signals (e.g., EEG, MEG).
- 16 December 2025
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 51 (4) , 722-731
Females have shorter scalp-to-cortex distances and receive stronger TMS electrical fields: Implications for clinical treatment
The strength of a given transcranial magnetic stimulation (TMS) pulse decays rapidly with distance. Male and female bone structure reliably differs by the shape of the frontal bone, mandible, and inion. Given the morphology of these structures constitutes much of the scalp-to-cortex distance (STCD), we hypothesized that females have shorter STCDs and thereby receive stronger TMS electrical field strengths, relative to males. Head models (n = 411; 197 female, 214 male) were constructed from MRIs of healthy participants (ages 18–90). STCD and peak electrical field strength were measured at 50 EEG 10–20 sites (SimNIBSv3.2). Linear models (bootstrapped and Benajamini-Hochberg multiple comparison-corrected) evaluated the influence of sex on STCD and electrical field strength. Females had significantly shorter STCDs at 27/50 sites and stronger TMS electrical fields at 18/50. When normalized by data collected at the motor cortex, females had significantly shorter STCD at 40/49 sites and stronger TMS electrical fields at 29/49 sites. The largest effect size differences were detected at the frontal, temporal, and occipital poles, and the cerebellum. Interestingly, STCD at the motor cortex was not different between sexes, suggesting the motor cortex-based dosing strategies produce unequal electrical fields between sexes. These data provide a mathematically grounded explanation for sex-differences in clinical outcome and may be relevant to other modalities that depend on electromagnetic signals (e.g., EEG, MEG).
- 14 July 2025
- Published by Springer Nature in Nature Mental Health
- Vol. 3 (8) , 859-869
Illuminating posterior targets for transcranial magnetic stimulation beyond the prefrontal cortex
Transcranial magnetic stimulation (TMS) is rapidly developing as a therapeutic tool for multiple psychiatric disorders. All current US Food and Drug Administration-cleared TMS indications for psychiatric illness target the frontal lobes. Historically, TMS target selection was based on reports of brain lesion locations that cause illness or functional neuroimaging correlates within the prefrontal cortex. In addition to prefrontal targets, however, these neuroimaging studies have consistently implicated posterior brain regions in a variety of psychiatric disorders. Thus far, these posterior regions have rarely been tested in TMS clinical trials. In this Perspective, we consider the role in psychiatric disorders of posterior regions such as the occipital cortex, precuneus, inferior parietal lobules and cerebellum. We synthesize preliminary evidence across the few existing TMS trials targeting posterior regions and consider the risks and benefits of stimulating posterior targets for the treatment of psychiatric illness.
- 14 July 2025
- Published by Springer Nature in Nature Mental Health
- Vol. 3 (8) , 859-869
Illuminating posterior targets for transcranial magnetic stimulation beyond the prefrontal cortex
Transcranial magnetic stimulation (TMS) is rapidly developing as a therapeutic tool for multiple psychiatric disorders. All current US Food and Drug Administration-cleared TMS indications for psychiatric illness target the frontal lobes. Historically, TMS target selection was based on reports of brain lesion locations that cause illness or functional neuroimaging correlates within the prefrontal cortex. In addition to prefrontal targets, however, these neuroimaging studies have consistently implicated posterior brain regions in a variety of psychiatric disorders. Thus far, these posterior regions have rarely been tested in TMS clinical trials. In this Perspective, we consider the role in psychiatric disorders of posterior regions such as the occipital cortex, precuneus, inferior parietal lobules and cerebellum. We synthesize preliminary evidence across the few existing TMS trials targeting posterior regions and consider the risks and benefits of stimulating posterior targets for the treatment of psychiatric illness.
- 1 March 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 270, 112641
Intermittent theta burst to the left dorsolateral prefrontal cortex promoted decreased alcohol consumption and improved outcomes in those with alcohol use disorder: A randomized, double-blind, placebo-controlled clinical trial
- 1 March 2025
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 270, 112641
Intermittent theta burst to the left dorsolateral prefrontal cortex promoted decreased alcohol consumption and improved outcomes in those with alcohol use disorder: A randomized, double-blind, placebo-controlled clinical trial
- 10 January 2024
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 48 (1) , 164-177
A pilot, randomized clinical trial: Left dorsolateral prefrontal cortex intermittent theta burst stimulation improves treatment outcomes in veterans with alcohol use disorder
Background: Transcranial magnetic stimulation (TMS) offers a promising treatment avenue to modulate brain function in alcohol use disorder (AUD). To the best of our knowledge, this pilot study is the first randomized, double‐blind, sham‐controlled trial to deliver intermittent theta burst stimulation to the left dorsolateral prefrontal cortex (DLPFC) among US veterans with AUD. We hypothesized that 20 sessions of real TMS are tolerable and feasible. As a secondary line of inquiry, we hypothesized that, relative to sham TMS, individuals receiving real TMS would experience greater reductions in 6‐month relapse rates, anhedonia, and alcohol cue‐reactivity.Methods: Veterans (n = 17, one woman) were enrolled in a double‐blind, sham‐controlled trial (2–3 sessions/day; 7–10 days; 600 pulses/session; 20 sessions). Pre‐ and posttreatment assessments included responses to self‐report questionnaires and functional magnetic resonance imaging measures of alcohol cue‐reactivity. Alcohol consumption was assessed for 6 months. Linear mixed‐effects models were constructed to predict posttreatment craving, mood, and cue‐reactivity.Results: Individuals who received active iTBS (n = 8) were less likely to relapse within 3 months after treatment than the sham‐treated group (n = 9) (OR = 12.0). Greater reductions in anhedonia were observed following active iTBS (Cohen's d = −0.59), relative to sham (d = −0.25). Alcohol cue‐reactivity was reduced following active iTBS and increased following sham within the left insula (d = −0.19 vs. 0.51), left thalamus (d = −0.28 vs. 0.77), right insula (d = 0.18 vs. 0.52), and right thalamus (d = −0.06 vs. 0.62).Conclusions: Relative to sham, we demonstrate that 20 sessions of real left DLPFC iTBS reduced the likelihood of relapse for at least 3 months. The potential utility of this approach is underscored by observed decreases in anhedonia and alcohol cue‐reactivity—strong predictors of relapse among veterans. These initial data offer a valuable set of effect sizes to inform future clinical trials in this patient population.
- 10 January 2024
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 48 (1) , 164-177
A pilot, randomized clinical trial: Left dorsolateral prefrontal cortex intermittent theta burst stimulation improves treatment outcomes in veterans with alcohol use disorder
Background: Transcranial magnetic stimulation (TMS) offers a promising treatment avenue to modulate brain function in alcohol use disorder (AUD). To the best of our knowledge, this pilot study is the first randomized, double‐blind, sham‐controlled trial to deliver intermittent theta burst stimulation to the left dorsolateral prefrontal cortex (DLPFC) among US veterans with AUD. We hypothesized that 20 sessions of real TMS are tolerable and feasible. As a secondary line of inquiry, we hypothesized that, relative to sham TMS, individuals receiving real TMS would experience greater reductions in 6‐month relapse rates, anhedonia, and alcohol cue‐reactivity.Methods: Veterans (n = 17, one woman) were enrolled in a double‐blind, sham‐controlled trial (2–3 sessions/day; 7–10 days; 600 pulses/session; 20 sessions). Pre‐ and posttreatment assessments included responses to self‐report questionnaires and functional magnetic resonance imaging measures of alcohol cue‐reactivity. Alcohol consumption was assessed for 6 months. Linear mixed‐effects models were constructed to predict posttreatment craving, mood, and cue‐reactivity.Results: Individuals who received active iTBS (n = 8) were less likely to relapse within 3 months after treatment than the sham‐treated group (n = 9) (OR = 12.0). Greater reductions in anhedonia were observed following active iTBS (Cohen's d = −0.59), relative to sham (d = −0.25). Alcohol cue‐reactivity was reduced following active iTBS and increased following sham within the left insula (d = −0.19 vs. 0.51), left thalamus (d = −0.28 vs. 0.77), right insula (d = 0.18 vs. 0.52), and right thalamus (d = −0.06 vs. 0.62).Conclusions: Relative to sham, we demonstrate that 20 sessions of real left DLPFC iTBS reduced the likelihood of relapse for at least 3 months. The potential utility of this approach is underscored by observed decreases in anhedonia and alcohol cue‐reactivity—strong predictors of relapse among veterans. These initial data offer a valuable set of effect sizes to inform future clinical trials in this patient population.
- Open Access
- 22 April 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (3) , 724-726
The importance of overlap: A retrospective analysis of electrical field maps, alcohol cue-reactivity patterns, and treatment outcomes for alcohol use disorder
- 22 April 2023
- Published by Elsevier in Brain Stimulation
- Vol. 16 (3) , 724-726
Open AccessThe importance of overlap: A retrospective analysis of electrical field maps, alcohol cue-reactivity patterns, and treatment outcomes for alcohol use disorder
- Open Access
- 14 March 2022
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 3 (2) , 301-310
Medial Prefrontal Cortex Theta Burst Stimulation Improves Treatment Outcomes in Alcohol Use Disorder: A Double-Blind, Sham-Controlled Neuroimaging Study
- 14 March 2022
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 3 (2) , 301-310
Open AccessMedial Prefrontal Cortex Theta Burst Stimulation Improves Treatment Outcomes in Alcohol Use Disorder: A Double-Blind, Sham-Controlled Neuroimaging Study
- 2 August 2021
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 45 (8) , 1672-1683
Regionally specific gray matter volume is lower in alcohol use disorder: Implications for noninvasive brain stimulation treatment
Background: There is growing interest in neuromodulation‐based therapeutics as tools for individuals with alcohol use disorder (AUD). Through electromagnetic induction, techniques such as transcranial magnetic stimulation (TMS) can noninvasively depolarize cortical cells in the induced electrical field and monosynaptic afferents. The ability of TMS to modulate the brain is dependent upon two factors, which may be compromised in individuals with AUD: (1) gray matter volume (GMV) at the site of stimulation and (2) scalp‐to‐cortex (STC) distance. This study tested the hypotheses that these aspects of neural architecture are compromised in AUD patients, and thus AUD patients may need a higher TMS dose to depolarize the cortex.Methods: High‐resolution magnetic resonance images were acquired from 44 individuals with AUD and 44 age‐matched healthy controls (n = 88). Whole‐brain voxel‐based morphometry was conducted. Subsequent region‐of‐interest analysis was performed at three EEG 10‐20 sites commonly used in TMS for AUD: FP1 (left frontal pole), F3 (left DLPFC), and C3 (left motor cortex). STC distance and TMS electric fields were assessed at these EEG sites.Results: Individuals with AUD had significantly lower GMV in the bilateral orbitofrontal cortices, supramarginal gyri, and the left DLPFC (voxel‐threshold p < 0.05, cluster‐threshold p < 0.05) and within all 3 TMS target locations, F (1, 264) = 14.12, p = 0.0002. There was no significant difference in STC distance between the AUD and the healthy control group at any tested cortical location, F (3, 252) = 1.906, p = 0.129.Conclusions: Individuals with AUD had significantly lower GMV in multiple areas of interest for TMS treatment; however, these volumetric reductions did not impact STC distance. Given previous studies that have shown TMS‐evoked changes in cortical and subcortical activity to be dependent on GMV, these data suggest that individuals with AUD may require higher doses of TMS to sufficiently modulate the neural circuits of interest.
- 2 August 2021
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 45 (8) , 1672-1683
Regionally specific gray matter volume is lower in alcohol use disorder: Implications for noninvasive brain stimulation treatment
Background: There is growing interest in neuromodulation‐based therapeutics as tools for individuals with alcohol use disorder (AUD). Through electromagnetic induction, techniques such as transcranial magnetic stimulation (TMS) can noninvasively depolarize cortical cells in the induced electrical field and monosynaptic afferents. The ability of TMS to modulate the brain is dependent upon two factors, which may be compromised in individuals with AUD: (1) gray matter volume (GMV) at the site of stimulation and (2) scalp‐to‐cortex (STC) distance. This study tested the hypotheses that these aspects of neural architecture are compromised in AUD patients, and thus AUD patients may need a higher TMS dose to depolarize the cortex.Methods: High‐resolution magnetic resonance images were acquired from 44 individuals with AUD and 44 age‐matched healthy controls (n = 88). Whole‐brain voxel‐based morphometry was conducted. Subsequent region‐of‐interest analysis was performed at three EEG 10‐20 sites commonly used in TMS for AUD: FP1 (left frontal pole), F3 (left DLPFC), and C3 (left motor cortex). STC distance and TMS electric fields were assessed at these EEG sites.Results: Individuals with AUD had significantly lower GMV in the bilateral orbitofrontal cortices, supramarginal gyri, and the left DLPFC (voxel‐threshold p < 0.05, cluster‐threshold p < 0.05) and within all 3 TMS target locations, F (1, 264) = 14.12, p = 0.0002. There was no significant difference in STC distance between the AUD and the healthy control group at any tested cortical location, F (3, 252) = 1.906, p = 0.129.Conclusions: Individuals with AUD had significantly lower GMV in multiple areas of interest for TMS treatment; however, these volumetric reductions did not impact STC distance. Given previous studies that have shown TMS‐evoked changes in cortical and subcortical activity to be dependent on GMV, these data suggest that individuals with AUD may require higher doses of TMS to sufficiently modulate the neural circuits of interest.
- Open Access
- 22 October 2020
- Published by Wiley in Human Brain Mapping
- Vol. 42 (1) , 128-138
Evaluating a novel MR‐compatible foot pedal device for unipedal and bipedal motion: Test–retest reliability of evoked brain activity
The purpose of this study was to develop and evaluate a new, open‐source MR‐compatible device capable of assessing unipedal and bipedal lower extremity movement with minimal head motion and high test–retest reliability. To evaluate the prototype, 20 healthy adults participated in two magnetic resonance imaging (MRI) visits, separated by 2–6 months, in which they performed a visually guided dorsiflexion/plantar flexion task with their left foot, right foot, and alternating feet. Dependent measures included: evoked blood oxygen level‐dependent (BOLD) signal in the motor network, head movement associated with dorsiflexion/plantar flexion, the test–retest reliability of these measurements. Left and right unipedal movement led to a significant increase in BOLD signal compared to rest in the medial portion of the right and left primary motor cortex (respectively), and the ipsilateral cerebellum (FWE corrected, p < .001). Average head motion was 0.10 ± 0.02 mm. The test–retest reliability was high for the functional MRI data (intraclass correlation coefficients [ICCs]: >0.75) and the angular displacement of the ankle joint (ICC: 0.842). This bipedal device can robustly isolate activity in the motor network during alternating plantarflexion and dorsiflexion with minimal head movement, while providing high test–retest reliability. Ultimately, these data and open‐source building instructions will provide a new, economical tool for investigators interested in evaluating brain function resulting from lower extremity movement.
- 22 October 2020
- Published by Wiley in Human Brain Mapping
- Vol. 42 (1) , 128-138
Open AccessEvaluating a novel MR‐compatible foot pedal device for unipedal and bipedal motion: Test–retest reliability of evoked brain activity
The purpose of this study was to develop and evaluate a new, open‐source MR‐compatible device capable of assessing unipedal and bipedal lower extremity movement with minimal head motion and high test–retest reliability. To evaluate the prototype, 20 healthy adults participated in two magnetic resonance imaging (MRI) visits, separated by 2–6 months, in which they performed a visually guided dorsiflexion/plantar flexion task with their left foot, right foot, and alternating feet. Dependent measures included: evoked blood oxygen level‐dependent (BOLD) signal in the motor network, head movement associated with dorsiflexion/plantar flexion, the test–retest reliability of these measurements. Left and right unipedal movement led to a significant increase in BOLD signal compared to rest in the medial portion of the right and left primary motor cortex (respectively), and the ipsilateral cerebellum (FWE corrected, p < .001). Average head motion was 0.10 ± 0.02 mm. The test–retest reliability was high for the functional MRI data (intraclass correlation coefficients [ICCs]: >0.75) and the angular displacement of the ankle joint (ICC: 0.842). This bipedal device can robustly isolate activity in the motor network during alternating plantarflexion and dorsiflexion with minimal head movement, while providing high test–retest reliability. Ultimately, these data and open‐source building instructions will provide a new, economical tool for investigators interested in evaluating brain function resulting from lower extremity movement.